Athersys (ATHX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Athersys Announces Financial Results for Fourth Quarter and Full Year 2019
March 16, 2020 4:05 PM EDTClinical trial results in Acute Respiratory Distress Syndrome (ARDS) supported Fast Track designation by FDA and designation by the Biomedical Advanced Research and Development Authority (BARDA) as a "Highly Relevant" program for COVID-19 and other pathogens
Management to host conference call at 4:30 PM EST today
CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2019 and annual 2019 financial results and recent highlights.
Throughout all of 2019, we made important progress in our key clinical... More
